Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease

[1]  中嶋 加央里,et al.  縦版Trail Making Testと横版Trail Making Testにおける成績の違いについての一考察 , 2017 .

[2]  J. Wiltfang,et al.  Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease , 2015, Molecular Neurobiology.

[3]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[4]  Amelia A. Assareh,et al.  The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study. , 2016, Current Alzheimer research.

[5]  Huadong Zhou,et al.  Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance , 2015, Molecular Neurobiology.

[6]  C. Rosano,et al.  Development and validation of risk index for cognitive decline using blood-derived markers , 2015, Neurology.

[7]  Huadong Zhou,et al.  Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery , 2015, Molecular Neurobiology.

[8]  G. Logroscino,et al.  Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? , 2014, Expert opinion on biological therapy.

[9]  A. Kribben,et al.  The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. , 2014, Kidney international.

[10]  Ming-Jang Chiu,et al.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. , 2013, ACS chemical neuroscience.

[11]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[12]  Deborah Blacker,et al.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.

[13]  A. Kribben,et al.  Relationship between Magnesium and Clinical Biomarkers on Inhibition of Vascular Calcification , 2011, American Journal of Nephrology.

[14]  F. Grodstein,et al.  Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis , 2011, Alzheimer's & Dementia.

[15]  F. Petermann.  Hospital Anxiety and Depression Scale, Deutsche Version (HADS-D) , 2011 .

[16]  Tamara B Harris,et al.  Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. , 2011, JAMA.

[17]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[18]  R. Mayeux,et al.  Plasma ß-amyloid and cognitive decline. , 2010, Archives of neurology.

[19]  H. Soininen,et al.  Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  D. Allen,et al.  Trail-Making Test , 2010 .

[21]  F. Grodstein,et al.  Ten-year change in plasma amyloid beta levels and late-life cognitive decline. , 2009, Archives of neurology.

[22]  C. Adler,et al.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[23]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[24]  M. Nakashima,et al.  Detection of amyloid β protein in the urine of Alzheimer's disease patients and healthy individuals , 2008, Neuroscience Letters.

[25]  V. Mathura,et al.  The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels , 2007, Neuroscience Letters.

[26]  N. Fullwood,et al.  Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis , 2006, The Lancet Neurology.

[27]  J. Sidtis,et al.  Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[28]  S. Younkin,et al.  Serum Creatinine Levels Correlate With Plasma Amyloid &bgr; Protein , 2002, Alzheimer disease and associated disorders.

[29]  S. Younkin,et al.  Serum creatinine levels correlate with plasma amyloid β protein , 2002 .

[30]  D. Galasko,et al.  Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. , 2000, Biochemical and biophysical research communications.

[31]  C. Nicholson,et al.  Clearance systems in the brain-implications for Alzheimer disease. , 2015, Nature reviews. Neurology.

[32]  L. Ferrucci,et al.  Usefulness of the multidimensional prognostic index (MPI) in the management of older patients with chronic kidney disease. , 2012, Journal of nephrology.

[33]  K. Blennow,et al.  Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. , 2012, Journal of Alzheimer's disease : JAD.

[34]  R. Mayeux,et al.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[35]  C. Caltagirone,et al.  Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. , 2009, Journal of Alzheimer's disease : JAD.

[36]  O. Godefroy,et al.  Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. , 2006, Lancet Neurology.

[37]  Klaus W. Lange,et al.  Regensburger Wortflüssigkeits-Test (RWT) , 2004 .

[38]  G. Bäumler,et al.  Farbe-Wort-Interferenztest (FWIT) nach J. R. Stroop , 1985 .